Cargando…
Changes of immunogenic profiles between a single dose and one booster influenza vaccination in hemodialysis patients – an 18-week, open-label trial
Annual influenza vaccination is recommended, but its efficacy in dialysis population is still controversial. Here we aimed to compare the dynamic changes of immune response between various influenza vaccination protocols in hemodialysis patients. A 18-week open label, non-randomized, controlled tria...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751607/ https://www.ncbi.nlm.nih.gov/pubmed/26869526 http://dx.doi.org/10.1038/srep20725 |
_version_ | 1782415614102470656 |
---|---|
author | Chang, Yu-Tzu Wang, Jen-Ren Lin, Meng-Te Wu, Chi-Jung Tsai, Ming-Song Wen-Chi, Chiang Lin Shih, Te-En Kuo, Te-Hui Song, Eing-Ju Sung, Junne-Ming |
author_facet | Chang, Yu-Tzu Wang, Jen-Ren Lin, Meng-Te Wu, Chi-Jung Tsai, Ming-Song Wen-Chi, Chiang Lin Shih, Te-En Kuo, Te-Hui Song, Eing-Ju Sung, Junne-Ming |
author_sort | Chang, Yu-Tzu |
collection | PubMed |
description | Annual influenza vaccination is recommended, but its efficacy in dialysis population is still controversial. Here we aimed to compare the dynamic changes of immune response between various influenza vaccination protocols in hemodialysis patients. A 18-week open label, non-randomized, controlled trial was conducted during 2011–2012. The efficacy between unvaccinated, one- and two-dose regimens were evaluated in 175 hemodialysis patients. Immunogenic profiles were assessed by hemagglutination-inhibition assays. At 3–9 weeks post-vaccination, antibody responses were similar between the one- and two-dose regimens, while the seroprotection rates (antibody titer ≥1:40) for influenza A were 55.6–82.5% in the adult (18–60 years) and 33.3–66.7% in the elderly (>60 years). Meanwhile, the seroprotection rates for influenza B were low (4.0–25.0%). By 18 weeks post-vaccination, the seroprotection rates for influenza A and B declined (0.0–33.3%) in both the adult and elderly receiving one- or two-dose regimens. Of dialysis patients, at most 2.4% developed moderate to severe adverse effects(myalgia and headache) after vaccination. In conclusion, the two-dose regimen could not improve immune responses than the one-dose regimen in hemodialysis patients; meanwhile the induced protective antibodies of both regimens could not be maintained for more than 4 months. Modification of current influenza vaccination strategy in dialysis population should be re-considered. |
format | Online Article Text |
id | pubmed-4751607 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-47516072016-02-22 Changes of immunogenic profiles between a single dose and one booster influenza vaccination in hemodialysis patients – an 18-week, open-label trial Chang, Yu-Tzu Wang, Jen-Ren Lin, Meng-Te Wu, Chi-Jung Tsai, Ming-Song Wen-Chi, Chiang Lin Shih, Te-En Kuo, Te-Hui Song, Eing-Ju Sung, Junne-Ming Sci Rep Article Annual influenza vaccination is recommended, but its efficacy in dialysis population is still controversial. Here we aimed to compare the dynamic changes of immune response between various influenza vaccination protocols in hemodialysis patients. A 18-week open label, non-randomized, controlled trial was conducted during 2011–2012. The efficacy between unvaccinated, one- and two-dose regimens were evaluated in 175 hemodialysis patients. Immunogenic profiles were assessed by hemagglutination-inhibition assays. At 3–9 weeks post-vaccination, antibody responses were similar between the one- and two-dose regimens, while the seroprotection rates (antibody titer ≥1:40) for influenza A were 55.6–82.5% in the adult (18–60 years) and 33.3–66.7% in the elderly (>60 years). Meanwhile, the seroprotection rates for influenza B were low (4.0–25.0%). By 18 weeks post-vaccination, the seroprotection rates for influenza A and B declined (0.0–33.3%) in both the adult and elderly receiving one- or two-dose regimens. Of dialysis patients, at most 2.4% developed moderate to severe adverse effects(myalgia and headache) after vaccination. In conclusion, the two-dose regimen could not improve immune responses than the one-dose regimen in hemodialysis patients; meanwhile the induced protective antibodies of both regimens could not be maintained for more than 4 months. Modification of current influenza vaccination strategy in dialysis population should be re-considered. Nature Publishing Group 2016-02-12 /pmc/articles/PMC4751607/ /pubmed/26869526 http://dx.doi.org/10.1038/srep20725 Text en Copyright © 2016, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Chang, Yu-Tzu Wang, Jen-Ren Lin, Meng-Te Wu, Chi-Jung Tsai, Ming-Song Wen-Chi, Chiang Lin Shih, Te-En Kuo, Te-Hui Song, Eing-Ju Sung, Junne-Ming Changes of immunogenic profiles between a single dose and one booster influenza vaccination in hemodialysis patients – an 18-week, open-label trial |
title | Changes of immunogenic profiles between a single dose and one booster influenza vaccination in hemodialysis patients – an 18-week, open-label trial |
title_full | Changes of immunogenic profiles between a single dose and one booster influenza vaccination in hemodialysis patients – an 18-week, open-label trial |
title_fullStr | Changes of immunogenic profiles between a single dose and one booster influenza vaccination in hemodialysis patients – an 18-week, open-label trial |
title_full_unstemmed | Changes of immunogenic profiles between a single dose and one booster influenza vaccination in hemodialysis patients – an 18-week, open-label trial |
title_short | Changes of immunogenic profiles between a single dose and one booster influenza vaccination in hemodialysis patients – an 18-week, open-label trial |
title_sort | changes of immunogenic profiles between a single dose and one booster influenza vaccination in hemodialysis patients – an 18-week, open-label trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751607/ https://www.ncbi.nlm.nih.gov/pubmed/26869526 http://dx.doi.org/10.1038/srep20725 |
work_keys_str_mv | AT changyutzu changesofimmunogenicprofilesbetweenasingledoseandoneboosterinfluenzavaccinationinhemodialysispatientsan18weekopenlabeltrial AT wangjenren changesofimmunogenicprofilesbetweenasingledoseandoneboosterinfluenzavaccinationinhemodialysispatientsan18weekopenlabeltrial AT linmengte changesofimmunogenicprofilesbetweenasingledoseandoneboosterinfluenzavaccinationinhemodialysispatientsan18weekopenlabeltrial AT wuchijung changesofimmunogenicprofilesbetweenasingledoseandoneboosterinfluenzavaccinationinhemodialysispatientsan18weekopenlabeltrial AT tsaimingsong changesofimmunogenicprofilesbetweenasingledoseandoneboosterinfluenzavaccinationinhemodialysispatientsan18weekopenlabeltrial AT wenchichianglin changesofimmunogenicprofilesbetweenasingledoseandoneboosterinfluenzavaccinationinhemodialysispatientsan18weekopenlabeltrial AT shihteen changesofimmunogenicprofilesbetweenasingledoseandoneboosterinfluenzavaccinationinhemodialysispatientsan18weekopenlabeltrial AT kuotehui changesofimmunogenicprofilesbetweenasingledoseandoneboosterinfluenzavaccinationinhemodialysispatientsan18weekopenlabeltrial AT songeingju changesofimmunogenicprofilesbetweenasingledoseandoneboosterinfluenzavaccinationinhemodialysispatientsan18weekopenlabeltrial AT sungjunneming changesofimmunogenicprofilesbetweenasingledoseandoneboosterinfluenzavaccinationinhemodialysispatientsan18weekopenlabeltrial |